Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
Krystal Biotech, Inc. (NASDAQ: KRYS ) is one of the top gene therapy stocks to buy according to hedge funds . On February 25, Guggenheim revised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $284 from $224 and reiterated a Buy rating on the shares following the company's fiscal Q4 report. Krystal Biotech, Inc. (NASDAQ:KRYS) announced its fiscal Q4 and full year 2025 financial results on February 17, reporting that it recorded $107.1 million and $389.1 million in VYJUVEK net product revenue for fiscal Q4 and full year 2025, respectively. Is Krystal Biotech, Inc. (KRYS) the Best Cancer Stock to Invest in for Long-Term Gain? The company further reported that it has secured over 660 reimbursement approvals for VYJUVEK in the United States and is continuing to maintain strong access nationwide. Steady VYJUVEK uptake is being driven by high patient demand since launch in Germany, France, and Japan, and Krystal Biotech's (NASDAQ:KRYS) estimates show that over 90 patients ha
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech to Present at TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Krystal Biotech's KB707 RMAT Win Opens New Lung Cancer Chapter [Yahoo! Finance]Yahoo! Finance
- Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 [Yahoo! Finance]Yahoo! Finance
- Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 2/17/26 - Beat
KRYS
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/3/26 - Form 4
- KRYS's page on the SEC website